Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)
Observational
Observational Model: Cohort, Time Perspective: Prospective
Progression-free survival with different Xeloda-based chemotherapy regimens
approximately 4 years
No
Clinical Trials
Study Director
Hoffmann-La Roche
Hungary: National Instutute of Pharmacy
ML27791
NCT01696695
July 2011
March 2014
Name | Location |
---|